BJC Reports (Aug 2024)

Temporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinoma

  • Luisa Bresadola,
  • David Weber,
  • Christoph Ritzel,
  • Martin Löwer,
  • Valesca Bukur,
  • Özlem Akilli-Öztürk,
  • Christian Schuster,
  • Alessandra Gargano,
  • Julia Becker,
  • Hisham Mehanna,
  • Barbara Schrörs,
  • Fulvia Vascotto,
  • Ugur Sahin,
  • Anthony Kong

DOI
https://doi.org/10.1038/s44276-024-00091-5
Journal volume & issue
Vol. 2, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Head and neck squamous cell carcinomas (HNSCCs) are heterogeneous in terms of origin and aetiology. In addition, there is uncertainty about the genetic evolution from initial diagnosis to recurrence after primary treatments and further disease progression following systemic treatment. Changes in the genetic profile have implications on the selection of appropriate treatments for patients, especially in the era of targeted therapies and immunotherapies. Methods We analysed a cohort of nine HNSCC patients with metachronous recurrence. All patients had paired primary and recurrent samples suitable for whole-exome sequencing, while transcriptomic data from seven patients could be analysed (multiple recurrent samples collected at different time points were available for three patients). Results At the genomic level, the recurrences shared a fraction of the somatic single nucleotide variants (SNVs) with the index primary tumours, but they also acquired many additional mutations, while losing only a few others. A similar behaviour was also observed when examining the changes of mutational signatures between primary and recurrent samples. Overall, recurrences appeared thus more genetically diverse than the respective primary tumours. The transcriptomic analysis showed that recurrent samples had lower immune cell presence, which was also confirmed by the multiplex immunofluorescence (IF) histology assays performed on the PhenoCycler platform. Several genes related to immune response were significantly downregulated compared to the primary samples. Conclusions Our results underline the importance of analysing multiple samples per patient to obtain a more complete picture of the patient’s tumour and advocate a re-biopsy in the event of recurrence and treatment failure, in order to select the most appropriate therapeutic strategy.